The group reaffirms pancreatic cancer promise with RMC-6236, but has it found the best dose?

Two years after being snubbed by GSK, Ideaya shows the promise of MAT2A inhibition.

The group abandons plans in lung cancer with Met exon 14 skipping, to focus on Met amplifications.

One of the German group’s biggest cancer hopes has fallen flat, raising more questions about targeting an apoptosis pathway.

Meanwhile, Bristol’s other competition in this disease looks set to come from China.

The CDK4/6 inhibitor flunks its phase 3 study – a result that should have been foreseen five years ago.

Combination efficacy looks similar to Kura’s, but adverse events with revumenib could raise concerns again.